Compare CASS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | ALLO |
|---|---|---|
| Founded | 1906 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.9M | 597.7M |
| IPO Year | 1996 | 2018 |
| Metric | CASS | ALLO |
|---|---|---|
| Price | $55.33 | $1.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $45.00 | $8.35 |
| AVG Volume (30 Days) | 65.9K | ★ 5.0M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 87.77 | 34.09 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $190,750,000.00 | N/A |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $4.39 | $142,416.42 |
| P/E Ratio | $37.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.07 | $1.04 |
| 52 Week High | $59.63 | $4.46 |
| Indicator | CASS | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 39.05 | 37.24 |
| Support Level | $51.22 | $1.59 |
| Resistance Level | $59.63 | $1.92 |
| Average True Range (ATR) | 1.39 | 0.11 |
| MACD | -0.37 | -0.04 |
| Stochastic Oscillator | 0.00 | 12.62 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).